Enfuvirtide biosimilar - Paras Biopharmaceuticals

Drug Profile

Enfuvirtide biosimilar - Paras Biopharmaceuticals

Latest Information Update: 12 Jun 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Paras Biopharmaceuticals Finland
  • Class Antiretrovirals; Antivirals; Env gene products; Peptide fragments; Viral fusion proteins
  • Mechanism of Action HIV fusion inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Research HIV infections

Most Recent Events

  • 20 May 2015 Early research in HIV infections in Finland (Parenteral) (Paras pipeline, May 2015)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top